Ketamine for Depression

Ketamine has emerged as one of the most significant breakthroughs in depression treatment in decades, particularly for patients who have not responded to standard antidepressants. Studies show that 60–70% of treatment-resistant patients experience significant relief, often within hours of their first infusion.

Treatment-Resistant Depression (TRD)

TRD is defined as depression that has not adequately responded to at least two different antidepressant medications at adequate doses. Approximately 30% of people with major depression have TRD, making it a significant public health challenge. Ketamine offers these patients a fast-acting alternative.

The Science Behind Ketamine for Depression

Ketamine blocks NMDA receptors, which leads to a rapid increase in glutamate transmission. This triggers AMPA receptor activation and downstream signaling that promotes synaptogenesis — the growth of new synaptic connections in the prefrontal cortex and hippocampus, areas critical for mood regulation.

Clinical Evidence

• Multiple randomized controlled trials have shown ketamine produces antidepressant effects within 2–4 hours
• Response rates of 50–70% in treatment-resistant populations
• FDA approved esketamine (Spravato) for TRD and MDD with suicidal ideation in 2019
• Effects typically last 2–3 weeks per treatment series; maintenance infusions can extend remission

The Treatment Protocol

Standard treatment for depression involves 6 IV ketamine infusions over 2–3 weeks. Each session lasts 40–60 minutes. Patients are monitored throughout. Many clinics also offer integration therapy sessions to maximize the neuroplastic window following treatment.

Who Is a Good Candidate?

You may be a good candidate for ketamine therapy if you have tried 2 or more antidepressants without adequate relief, experience significant side effects from standard medications, or need rapid relief from severe depressive symptoms or suicidal ideation.